[ad_1]
Abbott (NYSE: ABT) announces that its High Sensitive Troponin-I blood test, which is used to predict the risk of heart attack months or years in advance in otherwise healthy people, is now CE certified.
The test will be available on the company's ARCHITECT system for cardiac risk assessment.
Shares increase by a fraction after hours.
[ad_2]
Source link
